ArticleMMWR. Morbidity and mortality weekly report2024
Ceftriaxone-Resistant Gonorrhea - China, 2022.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Temporal and geographic trends in extended-spectrum cephalosporins resistance among Neisseria gonorrhoeae isolates worldwide: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Heterogeneity of azithromycin resistance markers inNew microbes and new infections · 2026Review
- Antimicrobial resistance in Neisseria gonorrhoeae isolates at the Bangrak STIs Center, Bangkok, Thailand and WGS of antimicrobial-resistant isolates, 2018-23.The Journal of antimicrobial chemotherapy · 2026Article
- Genetic Background Modulates Zoliflodacin and Gepotidacin Cross-Resistance and Fitness in Neisseria gonorrhoeae.The Journal of infectious diseases · 2026Article
- Article
- Limitations of Global Surveillance for Neisseria gonorrhoeae Antimicrobial Resistance.Emerging infectious diseases · 2026Review
- Antimicrobial-Resistant Neisseria gonorrhoeae of Public Health Concern, New South Wales, Australia, 2022-2024.Emerging infectious diseases · 2026Article
- Fluoroquinolone resistance-conferringbioRxiv : the preprint server for biology · 2026Article
- China's nationwide antimicrobial resistance surveillance networks: a systematic analysis from One Health perspective.The Lancet regional health. Western Pacific · 2026Review
- Doxy-PEP interest, awareness, and use among sexual and gender minorities in Brazil, Mexico, and Peru: findings from a web-based survey.Lancet regional health. Americas · 2026Article
- Stepwise evolution and clonal enrichment of gepotidacin resistance inAntimicrobial agents and chemotherapy · 2026Article
- Comparable immunogenicity from murine blood collection methods in intranasal gonococcal vaccination with ACP and MtrE supports refinement of preclinical vaccine studies.Scientific reports · 2026Article
- Age-Period-Cohort analysis of gonorrhea surveillance data in Eastern China from 2005 to 2024.BMC infectious diseases · 2026Article
- Treatment Diversification to Address the Continued Rise of Antimicrobial Resistance in Neisseria gonorrhoeae.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Repurposing epetraborole to combatAntimicrobial agents and chemotherapy · 2026Article
- Whole-genome characterization of seven multidrug-resistantFrontiers in microbiology · 2026Article
- First Study on Antimicrobial Susceptibility and Molecular Epidemiology ofInfection and drug resistance · 2026Article
- Clonal Expansion ofInfection and drug resistance · 2026Article
- Emergence, evolution and temporal spread of ceftriaxone-resistantEmerging microbes & infections · 2025Article
- Emerging epidemic of the Africa-type plasmid in penicillinase-producingEmerging microbes & infections · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gonorrhea is a widespread sexually transmitted infection; in 2022, China reported 96,313 cases of gonorrhea, making it the fourth most common notifiable infectious disease in the country after viral hepatitis, pulmonary tuberculosis, and syphilis. The rise in prevalence in antimicrobial-resistant strains, particularly the international spread of ceftriaxone-resistant clones, poses a formidable challenge to gonorrhea control. The China Gonococcal Resistance Surveillance Program (China-GRSP), established in 1987 and covering 19 of 34 provincial-level administrative units, continuously monitors gonococcal antimicrobial resistance. In 2022, 13 China-GRSP sentinel sites collected 2,804 gonococcal isolates, representing 2.9% of all cases reported in China, and 4.1% of cases reported in the 13 participating provinces. The prevalence of Neisseria gonorrhoeae resistance to ceftriaxone was 8.1%, approximately three times the 2017 rate of 2.9%; five provinces reported >10% ceftriaxone resistance. Resistance prevalences to cefixime, azithromycin, tetracycline, penicillin, and ciprofloxacin were 16.0%, 16.9%, 77.1%, 77.8%, and 97.6%, respectively. Only one case of spectinomycin resistance was reported. These data highlight a substantial increase in ceftriaxone resistance from 2017 to 2022. Effective diagnosis and treatment and appropriate management of sex partners are essential to protect the health of infected persons and prevent ongoing transmission of gonorrhea, including transmission of resistant strains. Identifying reasons for the spread of ceftriaxone-resistant N. gonorrhoeae in China could guide strategies, such as antibiotic stewardship, to mitigate the rising resistance rate and curb the spread of resistant strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.